RxDoctor Payments Data

Christopher Schaefer, DO

Urology · Lawrenceville, NJNPI 1679780407

Payments from drug & device makers

$4,353in general payments, 2019–2025

Across 191 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$865
  • Myriad Genetic Laboratories, Inc.$403
  • Antares Pharma, Inc.$305
  • Johnson & Johnson$233
  • Neotract Inc.$187
  • AbbVie$166
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$4,08894%
  • Education$2656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,353 in reported general payments places this provider in the 65th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$436,568
Medicare patients
807
Services billed
16,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide12$166,147
ErleadaApalutamide12$158,265
MyrbetriqMirabegron56$56,000
XyostedTestosterone Enanthate20$11,960
Tamsulosin Hcl647$9,628
Finasteride519$9,497
Dutasteride201$9,360
Silodosin71$6,762
Potassium Citrate ErPotassium Citrate31$4,892
Solifenacin Succinate61$3,349
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl26$3,254
Tadalafil79$2,384
Testosterone41$1,783
Alfuzosin Hcl ErAlfuzosin Hcl46$845
Testosterone Cypionate12$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$114$166,14712 claims
Johnson & JohnsonErleada$233$158,26512 claims
Astellas Pharma US IncMyrbetriq$865$56,00056 claims
Antares Pharma, Inc.Xyosted$305$11,96020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 401 urology providers in New Jersey.

Other urology in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →